Comparing MTI randomization procedures to blocked randomization.
Vance W Berger, Klejda Bejleri, Rebecca Agnor
https://pubmed.ncbi.nlm.nih.gov/26337607/Actively Recruiting
Led by University of Alberta · Updated on 2026-07-17
100
Participants Needed
2
Research Sites
N/A
Total Duration
This trial evaluates Tezepelumab, a newly approved medication for adults with severe asthma who experience sudden worsening symptoms that require emergency care. The study aims to determine if starting Tezepelumab in the Emergency Department can help control asthma symptoms and reduce repeated visits or the need for steroid treatments. Adults with a history of asthma and recent exacerbations are the focus, and the trial compares Tezepelumab to a placebo in a phase 4 randomized, double-blinded study. Participants are randomized to receive either Tezepelumab 210 mg or a matching placebo through subcutaneous injections every four weeks for 90 days. After this period, all participants enter an open-label extension where they receive Tezepelumab for an additional 90 days. The study tracks the proportion of patients returning to the Emergency Department for asthma exacerbations during the first 90 days and again by day 180, while also monitoring other asthma control measures and drug safety. During the study, participants undergo regular assessments including asthma control questionnaires, lung function tests, and blood tests to measure inflammatory markers. The primary outcome is the rate of moderate and severe asthma exacerbations by day 90. Safety and tolerability of the medication are monitored throughout, and participants are followed for a total of 180 days. This research is sponsored by the University of Alberta and aims to provide important data on managing severe asthma in emergency settings.
CONDITIONS
Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)
H
Hannah Anstruther, RRT
A
Amy May, RRT
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Alberta
Lead Sponsor
AstraZeneca
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 90 days
Participants receive either Tezepelumab or a placebo injection every four weeks for 90 days.
3 visits every 4 weeks
Duration - 90 days
All participants receive Tezepelumab injections every four weeks from Day 90 to Day 180.
1 visit at Day 90, then follow-up visits
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Vance W Berger, Klejda Bejleri, Rebecca Agnor
https://pubmed.ncbi.nlm.nih.gov/26337607/EuroQol Group
https://pubmed.ncbi.nlm.nih.gov/10109801/Elizabeth F Juniper, Jean Bousquet, Linda Abetz...
https://pubmed.ncbi.nlm.nih.gov/16226443/Wei Wang, Yan Li, Zhe Lv...
https://pubmed.ncbi.nlm.nih.gov/30185520/Elizabeth F Juniper, Klas Svensson, Ann-Christin Mörk...
https://pubmed.ncbi.nlm.nih.gov/15823451/Nicholas J Osborne, Ian Alcock, Benedict W Wheeler...
https://pubmed.ncbi.nlm.nih.gov/28500390/Jill M Baren, Edwin D Boudreaux, Barry E Brenner...
https://pubmed.ncbi.nlm.nih.gov/16478839/Irvin Mayers, Arsh Randhawa, Christina Qian...
https://pubmed.ncbi.nlm.nih.gov/37914234/Wenle Zhao, Yanqiu Weng
https://pubmed.ncbi.nlm.nih.gov/21893215/Sumita B Khatri, Jonathan M Iaccarino, Amisha Barochia...
https://pubmed.ncbi.nlm.nih.gov/34779751/University of Alberta
Lead Sponsor
AstraZeneca
Collaborating Sponsor